ADVERTISEMENT

Clinical Summary

Non-small cell lung cancer: tislelizumab shows better outcomes vs docetaxel

Miriam Davis, PhD   |   26 October 2022

Takeaway

  • The RATIONALE-303 trial of the experimental drug tislelizumab found 34%-47% improvement in OS over docetaxel in a phase 3 trial of pretreated patients with advanced NSCLC.

Why this matters

  • The findings will be used in the new drug application of tislelizumab, which is an anti-programmed cell death-1 (PD-1) immunoglobulin...

          

November Challenge

Ends in 10h
left
right

Topic Challenges

left
right